AETHLON MEDICAL INC
For the period ended Mar 31, 2026. Filed Jun 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Jun 10, 2026
AEMD$5.49+0.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Equity
FOR THE YEARS ENDED MARCH 31, 2026 AND 2025
| COMMON STOCK · ADDITIONAL PAID IN · ACCUMULATED · ACCUMULATED COMPREHENSIVE · TOTAL | ||||||
|---|---|---|---|---|---|---|
| SHARES | AMOUNT | CAPITAL | DEFICIT | LOSS | EQUITY | |
| BALANCE - MARCH 31, 2024 | 32,873 | $33 | $160,339,967 | $(154,566,728) | $(6,940) | $5,766,332 |
| Proceeds from Issuances of common stock for public offering | 101,250 | 102 | 3,539,805 | – | – | 3,539,907 |
| Issuance of common stock upon Class A and Class B warrant exercises, net | 123,131 | 123 | 4,206,281 | – | – | 4,206,404 |
| Issuance of common shares upon vesting of restricted stock units and net stock option exercises | 1,277 | 1 | (18,928) | – | – | (18,927) |
| Stock-based compensation expense | – | – | 415,234 | – | – | 415,234 |
| Warrant Inducement | 4,612,862 | – | – | 4,612,862 | ||
| Net loss | – | – | – | (13,388,089) | – | (13,388,089) |
| Other comprehensive loss | – | – | – | (10,193) | (10,193) | |
| BALANCE – MARCH 31, 2025 | 258,531 | $259 | $173,095,221 | $(167,954,817) | $(17,133) | $5,123,530 |
| Issuances of common stock for public offering, net | 500,000 | 500 | 3,743,966 | – | – | 3,744,466 |
| Issuances of pre-funded warrants and warrants to institutional investors (including exercise of existing warrants), net of offering costs | 210,555 | 210 | 2,917,412 | – | – | 2,917,622 |
| Exercise of pre-funded warrants | 595,897 | 596 | (536) | – | – | 60 |
| Issuance of common shares upon vesting of restricted stock units and net stock option exercises | 5,359 | 5 | (10,919) | – | – | (10,914) |
| Stock-based compensation expense | – | – | 278,547 | – | – | 278,547 |
| Rounding for reverse split | 107 | – | – | – | – | – |
| Net loss | – | – | – | (7,151,469) | – | (7,151,469) |
| Other comprehensive loss | – | – | – | – | (15,570) | (15,570) |
| BALANCE – MARCH 31, 2026 | 1,570,449 | $1,570 | $180,023,691 | $(175,106,286) | $(32,703) | $4,886,272 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.